DrugDashboards

Leader Tussin Cf

acetaminophen, dextromethorphan hydrobromide, guaifenesin · ACETAMINOPHEN 650 mg/20mL; DEXTROMETHORPHAN HYDROBROMIDE 20 mg/20mL; GUAIFENESIN 400 mg/20mL · Solution · Oral · Cardinal Health 110, LLC. dba Leader

NDC 70000-0739-01 · 1 BOTTLE in 1 CARTON / 118 mL in 1 BOTTLE · OTC MONOGRAPH DRUG · View full market →

The short version

6 companies supply this market — a reasonable cushion if one runs into trouble. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

Medicare Part D does not cover over-the-counter drugs — by law it pays only for products requiring a prescription.

How Part D pricing works →

NADAC price per unit

$0$0.01$0.02$0.03Jun 2026Sep 2026$0.0254
3 price points · per MLSource: CMS NADAC

Supply fragility

0● Low risk

Nothing here is signaling trouble: several manufacturers, no current shortage, no recent serious recalls, stable pricing. In drug supply, boring is the good outcome.

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for acetaminophen, dextromethorphan hydrobromide, guaifenesin (other) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program · Opioid Analgesic REMS Shared System REMS

Regulatory

Application
M012
TE code
—
Approval date
—
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of acetaminophen, dextromethorphan hydrobromide, guaifenesin (Solution)

LabelerStrengthFirst seenLast seen
Amazon.com Services LLCACETAMINOPHEN 650 mg/20mL; DEXTROMETHORPHAN HYDROBROMIDE 20 mg/20mL; GUAIFENESIN 400 mg/20mLJul 15, 2026Sep 2, 2026
Cardinal Health 110, LLC. dba LeaderACETAMINOPHEN 650 mg/20mL; DEXTROMETHORPHAN HYDROBROMIDE 20 mg/20mL; GUAIFENESIN 400 mg/20mLJul 15, 2026Sep 2, 2026
Cvs Woonsocket Prescription Center, IncorporatedACETAMINOPHEN 650 mg/20mL; DEXTROMETHORPHAN HYDROBROMIDE 20 mg/20mL; GUAIFENESIN 400 mg/20mLJul 15, 2026Sep 2, 2026
HyVee IncACETAMINOPHEN 650 mg/20mL; DEXTROMETHORPHAN HYDROBROMIDE 20 mg/20mL; GUAIFENESIN 400 mg/20mLJul 15, 2026Sep 2, 2026
L. Perrigo CompanyACETAMINOPHEN 650 mg/20mL; DEXTROMETHORPHAN HYDROBROMIDE 20 mg/20mL; GUAIFENESIN 400 mg/20mLJul 15, 2026Sep 2, 2026
Topco Associates LLCACETAMINOPHEN 650 mg/20mL; DEXTROMETHORPHAN HYDROBROMIDE 20 mg/20mL; GUAIFENESIN 400 mg/20mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Leader Tussin Cf — NDC 70000-0739-01," retrieved September 3, 2026, https://drugdashboards.com/drug/70000073901.

Free to cite with attribution — see how the data is put together.